EDP001
/ Edding Genor Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Development of EDP001, a tetravalent T Cell engager targeting CD19 and BCMA for B Cell lymphoma
(AACR 2026)
- "EDP001 is the first reported tetravalent TCE targeting CD19 and BCMA. The unique molecular design of EDP001 enables a deep depletion of primary B cells as well as various lymphoma lines in preclinical studies. EDP001 may represent a promising off-the-shelf therapeutics with a superior efficacy for the treatment of variety of B-cell lymphomas."
IO biomarker • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 1
Of
1
Go to page
1